Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment

[1]  A. Ho,et al.  Induction of Interleukin-1 Associated with Compensatory Dopaminergic Sprouting in the Denervated Striatum of Young Mice: Model of Aging and Neurodegenerative Disease , 1998 .

[2]  Y. Mitsumoto,et al.  Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. , 1998, Biochemical and biophysical research communications.

[3]  R. Roth,et al.  Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study , 1998, Brain Research.

[4]  G. Uhl.  Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease , 1998, Annals of neurology.

[5]  R. Roth,et al.  Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus) , 1997, Neuroscience.

[6]  R. Turner,et al.  Dopaminergic Neurons Intrinsic to the Primate Striatum , 1997, The Journal of Neuroscience.

[7]  J. Eberling,et al.  PET studies of functional compensation in a primate model of Parkinson's disease , 1997, Neuroreport.

[8]  S. Numan,et al.  Increased Expression of trkB mRNA in Rat Caudate‐Putamen Following 6–OHDA Lesions of the Nigrostriatal Pathway , 1997, The European journal of neuroscience.

[9]  H. Hung,et al.  The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression. , 1996, Brain research. Molecular brain research.

[10]  R. Roth,et al.  Early gestational mesencephalon grafts, but not later gestational mesencephalon, cerebellum or sham grafts, increase dopamine in caudate nucleus of MPTP-treated monkeys , 1996, Neuroscience.

[11]  R. Roth,et al.  Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys. , 1996, Cell transplantation.

[12]  Don M. Gash,et al.  Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys , 1995, Neurobiology of Aging.

[13]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[14]  C. Marsden,et al.  Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. , 1995, European journal of pharmacology.

[15]  J. Langston,et al.  Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions , 1994, Annals of neurology.

[16]  J. Schneider,et al.  Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism , 1994, Brain Research.

[17]  M. Sofroniew,et al.  Trophism, Transplantation, and Animal Models of Parkinson's Disease , 1993, Experimental Neurology.

[18]  A. Albanese,et al.  Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioural, morphological and biochemical correlates , 1993, Neuroscience.

[19]  C D Marsden,et al.  Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study , 1993, Synapse.

[20]  D. Riche,et al.  Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons , 1993, Neuroscience.

[21]  C. Marsden,et al.  Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. , 1993, European journal of pharmacology.

[22]  A. Graybiel,et al.  Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  F. Colpaert,et al.  Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease , 1991, Neuroscience.

[24]  J. Obeso,et al.  Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset , 1991, Brain Research.

[25]  R. Schwartzman,et al.  Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates , 1991, Brain Research.

[26]  H. Przuntek,et al.  Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease? , 1991, Neuroscience Letters.

[27]  J. Schneider.  Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys , 1990, Brain Research.

[28]  J. Langston,et al.  The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey , 1990, Brain Research.

[29]  G. Snyder,et al.  Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. , 1990, The Journal of pharmacology and experimental therapeutics.

[30]  S. Boyce,et al.  Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis) , 1990, Brain Research.

[31]  R. Roth,et al.  Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions , 1989, Neuroscience.

[32]  C. Marsden,et al.  Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. , 1989, Biochemical pharmacology.

[33]  A. Grace,et al.  Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism. , 1989, Molecular and chemical neuropathology.

[34]  Ian Q. Whishaw,et al.  Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats , 1988, Brain Research.

[35]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[36]  P. Bédard,et al.  Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys , 1988, Neuroscience Letters.

[37]  R. Robertson,et al.  MPTP-Induced Parkinsonism in the Monkey: Neurochemical Pathology, Complications of Treatment and Pathophysiological Mechanisms , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[38]  R. Roth,et al.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF , 1987, Brain Research.

[39]  Richard F. Martin,et al.  Primate neostriatal neurons containing tyrosine hydroxylase: Immunohistochemical evidence , 1987, Neuroscience Letters.

[40]  J. Langston,et al.  Older dopaminergic neurons do not recover from the effects of MPTP , 1987, Neuropharmacology.

[41]  D. Jacobowitz,et al.  Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density , 1986, Brain Research.

[42]  F. Colpaert,et al.  Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old java monkey [Macaca cynamolgus fascicularis (Raffles)] , 1986, Brain Research Bulletin.

[43]  I. Mitchell,et al.  Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus , 1985, Neuroscience Letters.

[44]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Wurtman,et al.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.

[46]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[47]  Y. Agid,et al.  Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. , 1973, Nature: New biology.

[48]  R. Roth,et al.  Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. , 1995, Cell transplantation.

[49]  R. Roth,et al.  Behavioral Effects of MPTP Administration in the Vervet Monkey , 1994 .